New Study Shows Big Savings and Health Benefits for Employers Covering Obesity Management Medications

Recent data from Aon, a global professional services firm, shows how access to obesity medications can improve health outcomes for employees and reduce medical costs for employers.  

The study gathered data from over 100,000 prescribed GLP-1 users from 2022-2024 and found that within two years, those taking GLP-1s saw a 44% reduction in risk of hospitalizations from major cardiovascular issues, along with substantial reductions in claims for osteoporosis, pneumonia and other health conditions. Likely due to these improved health outcomes, Aon researchers also found that medical spend growth for individuals on GLP-1s decreased.  

These findings make one thing clear: covering comprehensive obesity care, including GLP-1s, is good for both employers and their employees. In fact, the data Aon saw led them to launch a new program for their U.S. employees that combines access to obesity treatment with virtual support and adherence tools. 

With millions of Americans living with obesity lacking coverage for needed care, we call on all employers to follow Aon’s lead and cover evidence-based obesity care options, like GLP-1s. This would be a critical step toward creating a healthier, more equitable workforce.  

Advocates can help make comprehensive obesity care coverage in their workplace a reality by signing our employee petition. EveryBODY deserves coverage for obesity care—it’s only fair.